Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Therapeutic Strategies for MMAE-Resistant Bladder Cancer Through DPP4 Inhibition

ABSTRACT: Monomethyl auristatin E (MMAE) is used as the cytotoxic payload for enfortumab vedotin (EV) in the treatment of locally advanced and metastatic bladder cancer (BC). However, the development of resistance to MMAE in BC is a therapeutic problem. To explore the mechanism of resistance to MMAE in BC, we established MMAE-resistant BC cells (MR-BCs). RNA sequencing analysis showed that the expression of dipeptidyl peptidase 4 (DPP4, also called CD26) increased significantly in MR-BCs compared with parental BC cells. Knock down of DPP4 expression using small interfering RNA inhibited the viability of MR-BCs. In addition, the DPP4 inhibitor sitagliptin suppressed the proliferation, migration, and invasion of BC cells, and cotreatment with MMAE effectively induced cell apoptosis, arrested cells in the G2M phase of the cell cycle, increased reactive oxygen species production by inhibiting the AKT pathway, and significantly inhibited the in vivo growth of MMAE-resistant cells. This study provides insights into the use of DPP4 inhibitors as a treatment strategy for MMAE-resistant BC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE306410 | GEO | 2025/08/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Enfortumab Vedotin Induces Immunogenic Cell Death and Shows Enhanced Preclinical Antitumor Activity When Combined With a PD-1 Inhibitor

Project description:Enfortumab vedotin is a Nectin-4-directed antibody–drug conjugate designed to deliver the microtubule-disrupting agent monomethyl auristatin E (MMAE) in tumor cells. Using preclinical models of urothelial cancer (UC), we expand the understanding of the multifaceted mechanism of action for enfortumab vedotin that includes direct cytotoxicity on Nectin-4–positive tumor cells, indirect bystander effect on neighboring Nectin-4–negative tumor cells, and MMAE-mediated induction of immunogenic cell death (ICD) and associated increase in activated immune cells in the tumor microenvironment. Importantly, vaccination with enfortumab vedotin-treated tumor cells drives antitumor immunity and provides protection against rechallenge in mice. MMAE-mediated ICD induction modulates the tumor microenvironment in a complementary manner to immune checkpoint inhibition. Accordingly, enfortumab vedotin plus PD-1 inhibitor shows enhanced antitumor activity in vivo. These preclinical results demonstrate the underlying mechanisms consistent with the significantly improved clinical outcomes observed for enfortumab vedotin plus pembrolizumab relative to chemotherapy in the first-line treatment of la/mUC.

2024-04-19 | GSE264352 | GEO

Antibody-drug conjugate stability probed by variable-temperature electrospray ionization mass spectrometry

Project description:The stability of hinge-deleted and mutated IgG4, as well as lysine- (Trastuzumab emtansine) and cysteine-based ADCs (Enfortumab vedotin, Brentuximab vedotin) was probed with vT-ESI-MS.

2025-05-22 | PXD063887 | Pride

High glucose associated YTHDC1 lactaylation reduces the sensitivity of bladder cancer to enfortumab vedotin therapy

Project description:Hyperglycemia has been reported to be a risk factor for bladder cancer (BC). Enfortumab vedotin (EV), the first antibody-drug conjugates targeting NECTIN4, has shown promising clinical efficacy in patients with advanced BC. However, the impact of high glucose status on EV sensitivity remains unclear. In this study, we discover that EV treatment in BC patients with diabetes is less effective than those of patients with normal blood glucose. The subsequent cell and mice studies indicate that high glucose decreases the sensitivity of BC cells to EV. We previously reported that high glucose results in decreased protein levels of YTHDC1, promoting the tumorigenesis of BC cells. Our study identifies a high glucose associated lactate-AARS1-YTHDC1-JUND-NECTIN4 axis that affects EV sensitivity in BC. Targeting this axis with JUND activator or β-alanine may offer therapeutic strategies to enhance the sensitivity of BC cells to EV.

2025-03-10 | GSE291592 | GEO

Therapeutic Strategies for MMAE-Resistant Bladder Cancer Through DPP4 Inhibition

Project description:Therapeutic Strategies for MMAE-Resistant Bladder Cancer Through DPP4 Inhibition

| PRJNA1310591 | ENA

Chemically induced expansion of type 2 alveolar epithelial cell promotes regenerative lower airway repair

Project description:To evaluate the effect of DPP4 inhibitor on regenerative repair of the lung upon injury, we carried out a single cell RNA sequencing study. In this study, orally administered sitagliptin was tested in LPS-induced lung injury model, followed by longitudinal single cell transcriptomic analysis with lung cells harvested at indicated time points.

2024-03-27 | GSE262393 | GEO

Gene expression in mouse tracheal basal cells

2009-07-02 | GSE15724 | GEO

The TFIID subunit TAF4 is required for pancreatic beta cell function and identity [RNA-seq]

Project description:We selectively inactivated the Taf4 subunit of general transcription factor TFIID in adult murine pancreatic beta cells (BCs). Taf4 inactivation rapidly diminishes expression of critical genes involved in BC function leading to increased glycaemia, lowered blood insulin levels, defective glucose-stimulated insulin secretion and in the longer term reduced BC mass through apoptosis of a subpopulation of BCs. Nevertheless, glycaemia and blood insulin levels are stabilised after 11 weeks with mutant animals showing long term survival. Bulk RNA-seq and ATAC-seq and single cell RNA-seq on isolated Langerhans islets show that Taf4 loss leads to major remodelling of chromatin accessibility and gene expression not only in targeted BCs, but also alpha and delta cells. One week after Taf4-loss cells with mixed BC, alpha and/or delta cell identities were observed as well as a population trans-differentiating into alpha cells. Trans-differentiation was associated with the concerted action of the Mafb, Mafg, Bptf and Foxp1 transcription factors. Taf4 is therefore essential for BC function and identity and we identify a novel set of factors associated with BC trans-differentiation.

2021-06-01 | GSE151364 | GEO

The TFIID subunit TAF4 is required for pancreatic beta cell function and identity [ATAC-seq]

2021-06-01 | GSE151363 | GEO

The TFIID subunit TAF4 is required for pancreatic beta cell function and identity [single-cell RNA-seq]

2021-06-01 | GSE151365 | GEO

Transcription profiling of mouse tracheal basal cells

Project description:Epithelial basal cells (BCs) are an important stem cell population of the airways. We purified BCs from a KRT5-GFP transgenic mouse line and used Affymetrix arrays to compare there gene expression to that of non-BC epithelium. Experiment Overall Design: Three populations of cells were obtained by FACS: 1. KRT5-GFP-, lectin- columnar epithelium. 2. KRT5-GFP-, lectin+ BCs. 3. KRT5-GFP+, lectin+ BCs. Three biological replicates of each sample were hybridized to Affymetrix microarray.

2009-07-11 | E-GEOD-15724 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data